Unnamed: 0 float64 0 336 ⌀ | Ticker stringclasses 2
values | Year stringclasses 8
values | Text stringlengths 4 2.95k | Embedding stringlengths 9 34.6k |
|---|---|---|---|---|
200 | LLY | 2015 | The main coverage expansion provisions of the Affordable Care Act (ACA) are now in effect through both the launch of state-based exchanges and the expansion of Medicaid. An emerging trend has been the prevalence of benefit designs containing high out-of-pocket costs for patients, particularly for pharmaceuticals. In ad... | [-0.008590491488575935, 0.00313391350209713, 0.028868358582258224, -0.030753418803215027, -0.03522370755672455, 0.009485894814133644, -0.009189670905470848, -0.001296820817515254, -0.024128777906298637, 0.01806965284049511, 0.020708737894892693, 0.021907098591327667, 0.0027838307432830334, 0.0029740198515355587, -0.012... |
201 | LLY | 2015 | International operations also are generally subject to extensive price and market regulations. Cost-containment measures exist in a number of countries, including additional price controls and mechanisms to limit reimbursement for our products. Such policies are expected to increase in impact and reach, given the press... | [0.0032650455832481384, -0.02013719268143177, -0.0030212379060685635, -0.028123540803790092, 0.004661997314542532, 0.019320107996463776, 0.0029718175064772367, 0.013929982669651508, -0.0214550718665123, -0.01379819493740797, -0.007913864217698574, 0.005551565904170275, 0.0022931096609681845, -0.0033408235758543015, -0.... |
202 | LLY | 2015 | We are subject to income taxes in the U.S. and numerous foreign jurisdictions. Changes in the relevant tax laws, regulations, administrative practices, principles, and interpretations could adversely affect our future effective tax rates. The U.S. and a number of other countries are actively considering or enacting cha... | [-0.008631388656795025, -0.04704298824071884, -0.0013474520528689027, -0.04429838806390762, -0.0003801482089329511, 0.003108518198132515, -0.01931481622159481, 0.006383764557540417, -0.002303734188899398, -0.0022588458377867937, 0.011401640251278877, 0.0026516190264374018, 0.022751979529857635, 0.008592912927269936, -0... |
203 | LLY | 2015 | Numbers may not add due to rounding. | [-0.008122851140797138, -0.008246813900768757, 0.028420191258192062, -0.0178376492112875, -0.017668016254901886, -0.003810236928984523, -0.03303945064544678, -0.02540592849254608, -0.01646753028035164, -0.02672385238111019, 0.008971019648015499, 0.025014465674757957, -0.021517399698495865, 0.003350268118083477, -0.0113... |
204 | LLY | 2015 | (1) U.S. revenue includes revenue in Puerto Rico. | [-0.002270389348268509, -0.026054497808218002, 0.00866758357733488, -0.010976782999932766, 0.016377851366996765, -0.022458096966147423, 0.003209916641935706, -0.0053557902574539185, 0.014864258468151093, -0.0334542840719223, 0.012102275155484676, 0.01859002560377121, 0.003389413235709071, -0.010905630886554718, -0.0095... |
205 | LLY | 2015 | Numbers may not add due to rounding. | [-0.00807367917150259, -0.008230196312069893, 0.028460044413805008, -0.017790788784623146, -0.017621228471398354, -0.0037694559432566166, -0.03305121511220932, -0.025486217811703682, -0.01644734852015972, -0.02667314000427723, 0.00895408820360899, 0.02506883814930916, -0.021586330607533455, 0.003342294367030263, -0.011... |
206 | LLY | 2015 | In the U.S., the volume increase in 2015 was driven by the inclusion of revenue from Novartis AH and increased volumes for several pharmaceutical products, partially offset by the residual impact of the loss of exclusivity for Cymbalta and Evista. | [-0.0009340893011540174, -0.02767188474535942, 0.027880730107426643, -0.023051202297210693, -0.015702489763498306, 0.015010692179203033, -0.010011479258537292, -0.002566502196714282, -0.02606639452278614, -0.010912121273577213, 0.021589292213320732, 0.015689436346292496, -0.0015133062843233347, 0.003021717770025134, -0... |
207 | LLY | 2015 | Outside the U.S., the volume increase in 2015 was driven by the inclusion of revenue from Novartis AH and increased volumes for several pharmaceutical products. | [0.0045220195315778255, -0.01767255738377571, 0.009998435154557228, -0.013212217018008232, -0.006028276868164539, 0.007998747751116753, -0.004976493772119284, -0.0032851998694241047, -0.02539862133562565, -0.00927127618342638, 0.025294741615653038, 0.005521862767636776, 0.001084245857782662, -0.004132470116019249, -0.0... |
208 | LLY | 2015 | On a pro forma basis, which reflects the 2014 revenues of Novartis AH as described in Note 3 to the consolidated financial statements, our consolidated volume in 2015 would have increased by 2 percent compared with 2014. | [-0.00800390262156725, -0.01951952464878559, 0.0002935779048129916, -0.006952949799597263, 0.005741790868341923, 0.014905586838722229, -0.009971234947443008, -0.003176889382302761, -0.02345419116318226, -0.010028908960521221, 0.034296948462724686, 0.0160078052431345, 0.0032906357664614916, -0.019980918616056442, 0.0001... |
209 | LLY | 2015 | (1) U.S. revenue includes revenue in Puerto Rico. | [-0.002270389348268509, -0.026054497808218002, 0.00866758357733488, -0.010976782999932766, 0.016377851366996765, -0.022458096966147423, 0.003209916641935706, -0.0053557902574539185, 0.014864258468151093, -0.0334542840719223, 0.012102275155484676, 0.01859002560377121, 0.003389413235709071, -0.010905630886554718, -0.0095... |
210 | LLY | 2015 | (2) Other pharmaceutical products includes revenue of $175.6 million and $46.1 million in 2015 and 2014, respectively, for Erbitux®. The 2015 revenue is primarily associated with net product revenue from third parties subsequent to the transfer of commercialization rights in the U.S. and Canada (collectively, North Ame... | [-0.011810699477791786, -0.009749552235007286, -0.006863946560770273, -0.019564537331461906, -0.0006428815540857613, 0.006049302872270346, -0.005954424384981394, -0.013544679619371891, -0.00988041888922453, -0.004334951750934124, 0.008107177913188934, 0.0030671830754727125, -0.019158851355314255, -0.007092962972819805,... |
211 | LLY | 2015 | Revenues of Humalog, our injectable human insulin analog for the treatment of diabetes, increased 9 percent in the U.S., driven by higher realized prices and, to a lesser extent, increased volume. Revenues outside the U.S. decreased 8 percent, driven by the unfavorable impact of foreign exchange rates, partially offset... | [-0.020089196041226387, -0.016422629356384277, 0.017076458781957626, 0.0005152103258296847, 0.020666103810071945, -0.011743269860744476, -0.01111508160829544, -0.013781676068902016, -0.041845012456178665, -0.022294264286756516, 0.001717901905067265, 0.01990971341729164, -0.008108753710985184, -0.014627806842327118, -0.... |
212 | LLY | 2015 | Revenues of Alimta, a treatment for various cancers, decreased 5 percent in the U.S., driven by decreased demand and, to a lesser extent, lower realized prices. Revenues outside the U.S. decreased 15 percent, driven by the unfavorable impact of foreign exchange rates and, to a lesser extent, lower realized prices, part... | [-0.007474956102669239, -0.018668223172426224, 0.018706556409597397, -0.01813155971467495, 0.0020987377502024174, 0.015461020171642303, -0.005341080017387867, -0.018617114052176476, -0.02379208244383335, -0.005769132636487484, 0.015269354917109013, 0.02713984064757824, 0.015001023188233376, -0.007992452941834927, -0.00... |
213 | LLY | 2015 | Revenues of Cialis, a treatment for erectile dysfunction and benign prostatic hyperplasia, increased 21 percent in the U.S., driven by higher realized prices. Revenues outside the U.S. decreased 16 percent, driven by the unfavorable impact of foreign exchange rates. | [-0.0017355948220938444, -0.010843457654118538, 0.027307547628879547, -0.004712733440101147, 0.011805894784629345, 0.005303028505295515, -0.010541894473135471, -0.006852551829069853, -0.03629029542207718, -0.020788641646504402, -0.0030781945679336786, 0.029540402814745903, 0.011940635740756989, 0.0075711715035140514, 0... |
214 | LLY | 2015 | Revenues of Forteo, an injectable treatment for osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid-induced osteoporosis in men and postmenopausal women, increased 14 percent in the U.S., driven by higher realized prices, partially offset by decreased volume. Revenues outside t... | [-0.017559505999088287, -0.027165044099092484, -0.0019802339375019073, -0.031102390959858894, 0.008759934455156326, 0.002117314375936985, -0.03876568004488945, -0.011098559014499187, -0.008581564761698246, -0.00655013183131814, 0.024139367043972015, 0.015828659757971764, 0.006642619613558054, -0.0030669679399579763, 0.... |
215 | LLY | 2015 | Revenues of Humulin, an injectable human insulin for the treatment of diabetes, increased 7 percent in the U.S., driven by higher realized prices and, to a lesser extent, wholesaler buying patterns, partially offset by decreased demand. Revenues outside the U.S. decreased 21 percent, driven by decreased volume, primari... | [-0.021182430908083916, -0.023609584197402, 0.007028361316770315, 0.01144785713404417, 0.013991826213896275, -0.015536378137767315, -0.005723928567022085, -0.014783571474254131, -0.034810833632946014, -0.028762416914105415, 0.010422482155263424, 0.014614838175475597, -0.0072814603336155415, -0.011369980871677399, 0.002... |
216 | LLY | 2015 | Revenues of Cymbalta, a product for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, chronic musculoskeletal pain, and the management of fibromyalgia, decreased 66 percent in the U.S. due to the loss of U.S. patent exclusivity in December 2013. Revenues out... | [-0.014938585460186005, -0.017257997766137123, 0.030899284407496452, -0.020258819684386253, -0.012101564556360245, 0.005405409261584282, -0.010607706382870674, -0.01893531158566475, -0.0030139251612126827, -0.022905832156538963, 0.0181752797216177, 0.024072090163826942, -0.002466832287609577, 0.015986908227205276, -0.0... |
217 | LLY | 2015 | Revenues of Zyprexa, a treatment for schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance, increased 31 percent in the U.S., driven by adjustments to the return reserve resulting from the expiration of the period to return expired product for credit. Revenues outside ... | [0.003639258909970522, -0.0077711972407996655, 0.04267260804772377, -0.014005234465003014, -0.005038468632847071, 0.0017539388500154018, 0.004867672920227051, -0.01392640545964241, 0.0010576185304671526, -0.027011971920728683, 0.0006823610165156424, 0.022164005786180496, -0.00012101438915124163, -0.0036491125356405973,... |
218 | LLY | 2015 | Revenues of Strattera, a treatment for attention-deficit hyperactivity disorder, increased 11 percent in the U.S., driven by higher realized prices and, to a lesser extent, increased demand. Revenues outside the U.S. decreased 1 percent, driven by the unfavorable impact of foreign exchange rates, largely offset by incr... | [-0.00542971957474947, 0.008450501598417759, 0.028574099764227867, -0.02202640287578106, 0.0029198757838457823, 0.01133353915065527, -0.013146649114787579, -0.026318924501538277, -0.016926631331443787, -0.000812455837149173, 0.013326037675142288, 0.016631919890642166, 0.0004344576445873827, 0.011897332966327667, 0.0095... |
219 | LLY | 2015 | Revenues of Effient, a product for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are managed with an artery-opening procedure known as percutaneous coronary intervention, including patients undergoing angioplasty, atherectomy, or stent placem... | [-0.028210757300257683, -0.007381814997643232, -0.015851758420467377, 0.0021426742896437645, 0.020325180143117905, 0.006599302403628826, 0.005239140707999468, -0.010538733564317226, -0.039226386696100235, -0.0122380955144763, 0.014763629995286465, 0.017316032201051712, -0.012547070160508156, -0.005954484920948744, -0.0... |
220 | LLY | 2015 | Revenues of Evista, a product for the prevention and treatment of osteoporosis in postmenopausal women and for reduction of risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer, decreased 70 percent in the U.S., due to the loss of pate... | [-0.018347902223467827, -0.033817194402217865, 0.0052580032497644424, -0.003834906267002225, 0.010775340721011162, 0.016662228852510452, -0.02064301073551178, -0.010600290261209011, -0.013589117676019669, -0.01812746934592724, 0.008344081230461597, 0.0018039942951872945, 0.009011867456138134, -0.00265493500046432, -0.0... |
221 | LLY | 2015 | Revenues of animal health products in the U.S. increased 21 percent and animal health product revenues outside the U.S. increased 53 percent. The increases were driven by the inclusion of revenue from Novartis AH. | [0.001104156021028757, -0.004782498348504305, 0.01353734452277422, -0.004423157777637243, 0.008545775897800922, -0.007141080219298601, -0.002953127259388566, -0.011832109652459621, -0.02346821501851082, -0.0073828184977173805, 0.017379023134708405, -0.0018375377403572202, -0.002539885463193059, -0.014844038523733616, 0... |
222 | LLY | 2015 | On a pro forma basis, which reflects the 2014 revenues of Novartis AH as described in Note 3 to the consolidated financial statements, revenues of animal health products in the U.S. would have decreased 1 percent, driven primarily by decreased volume in food animal products. Revenues outside the U.S. would have decreas... | [-0.0064267124980688095, -0.015701739117503166, -0.005290661007165909, 0.005451083183288574, 0.011360515840351582, 0.0068163094110786915, 0.001825212617404759, -0.011196820065379143, -0.02389964461326599, -0.01099383644759655, 0.02177814207971096, 0.01423502154648304, 0.0011229559313505888, -0.01122301071882248, -0.006... |
223 | LLY | 2015 | Gross margin as a percent of total revenue was 74.8 percent in 2015, essentially flat compared with 2014 as the unfavorable impacts of the inclusion of Novartis AH and inventory step-up and amortization costs were offset by the favorable impact of foreign exchange rates on international inventories sold. | [-0.008847088553011417, -0.0026190343778580427, 0.012124503962695599, -0.0065580494701862335, 0.0018640699563547969, -0.010501893237233162, -0.011731728911399841, -0.007494913414120674, -0.02451944164931774, -0.019960680976510048, 0.0163162462413311, 0.018556993454694748, -0.005241288337856531, 0.003130929311737418, 0.... |
224 | LLY | 2015 | Research and development expenses increased 1 percent to $4.80 billion in 2015, driven primarily by higher late-stage clinical development costs, the inclusion of Novartis AH, and an increase in charges associated with the termination of late-stage molecules, primarily evacetrapib and basal insulin peglispro, of approx... | [0.0006999886245466769, -0.010386715643107891, 0.008832642808556557, -0.034438781440258026, 0.006032688543200493, 0.005111392121762037, 0.010399830527603626, -0.0028425767086446285, -0.028091344982385635, 0.0009549024980515242, 0.002573728561401367, 0.010537533089518547, -0.004258946981281042, 0.0016999723156914115, -0... |
225 | LLY | 2015 | Marketing, selling, and administrative expenses decreased 1 percent to $6.53 billion in 2015, due to the favorable impact of foreign exchange rates and a 2014 charge associated with the U.S. Drug Fee, partially offset by the inclusion of Novartis AH and expenses related to new product launches. | [-0.017143631353974342, 0.002202036790549755, 0.000645121734123677, -0.01752687245607376, -0.01018142607063055, -0.0017229861114174128, 0.0006411296781152487, 0.001248725806362927, -0.011695226654410362, -0.01276830118149519, 0.02229183167219162, 0.01063492801040411, 0.009172226302325726, 0.010200588963925838, 6.891345... |
226 | LLY | 2015 | We recognized acquired IPR&D charges of $535.0 million in 2015 resulting from various collaboration agreements, primarily with Pfizer, as well as the consideration paid to acquire the worldwide rights to Locemia's intranasal glucagon. There were $200.2 million of acquired IPR&D charges in 2014 related to various collab... | [-0.007203735411167145, -0.009600505232810974, 0.031017016619443893, -0.03512576222419739, 0.008412190712988377, 0.011144641786813736, -0.002341381972655654, -0.0021768976002931595, -0.01123863272368908, -0.016112735494971275, 0.02219529263675213, 0.0028751161880791187, -0.011372906155884266, 0.003324930090457201, 0.00... |
227 | LLY | 2015 | We recognized asset impairment, restructuring, and other special charges of $367.7 million in 2015. The charges relate to severance costs, integration costs for Novartis AH, and asset impairments. In 2014, we recognized charges of $468.7 million for asset impairment, restructuring, and other special charges. The charge... | [-0.024010591208934784, -0.00689861411228776, 0.025848470628261566, -0.019757211208343506, 0.0010272436775267124, 0.015621980652213097, 0.0016614764463156462, 0.00970794539898634, -0.010987897403538227, -0.011453931219875813, 0.002254685154184699, 0.02240900881588459, -0.006406324915587902, 0.009287858381867409, 0.0048... |
228 | LLY | 2015 | Other—net, (income) expense was income of $100.6 million in 2015, compared with income of $340.5 million in 2014. Other income in 2015 included net gains of $236.7 million on investments, partially offset by a net charge of $152.7 million related to the repurchase of $1.65 billion of debt. Other income in 2014 included... | [-0.02535139210522175, -0.028313186019659042, 0.014534971676766872, -0.014052212238311768, 0.0069021545350551605, 0.0015860929852351546, 0.0030890076886862516, 0.004341572523117065, -0.005055926274508238, -0.016622580587863922, 0.01837095245718956, 0.024946918711066246, -0.011057799682021141, 0.003946884069591761, -0.0... |
229 | LLY | 2015 | Our effective tax rate was 13.7 percent in 2015, compared with 20.3 percent in 2014. The effective tax rate for 2014 reflects the impact of a $119.0 million nondeductible charge associated with the U.S. Drug Fee. The decrease in the tax rate for 2015 compared with 2014 is primarily due to a favorable tax impact of the ... | [-0.036905985325574875, 0.002946724183857441, -0.007765256799757481, -0.044069934636354446, -0.0031471597030758858, -0.022914297878742218, 0.00688592717051506, -0.016940027475357056, -0.023910008370876312, -0.011631721630692482, 0.014741703867912292, 0.017444349825382233, 0.010351520963013172, 0.019345253705978394, -0.... |
230 | LLY | 2015 | (1) Operating expense consists of research and development and marketing, selling, and administrative expenses. | [-0.0005550310015678406, 9.03308973647654e-05, -0.014168312773108482, -0.029981160536408424, -0.0033112105447798967, -0.00033543005702085793, 0.004952584393322468, -0.0007139501394703984, -0.00812147930264473, -0.017609188333153725, 0.014282165095210075, 0.03597739338874817, -0.0031847076024860144, 0.001807408640161156... |
231 | LLY | 2015 | Revenue and gross margin decreased in 2014. The decrease in operating expense in 2014 was due to decreases in both research and development and marketing, selling, and administrative expenses. The decreases in net income and EPS for 2015 were due to lower gross margin, higher asset impairment, restructuring, and other ... | [-0.028043359518051147, -0.008362019434571266, -0.0035181669518351555, -0.028043359518051147, -0.0036743173841387033, -0.005462081637233496, 0.0073167672380805016, -0.0050286841578781605, -0.010223079472780228, -0.018279170617461205, 0.019592110067605972, 0.030873188748955727, 0.011663488112390041, 0.003757172729820013... |
232 | LLY | 2015 | Certain items affect the comparisons of our 2014 and 2013 results. The 2014 highlighted items are summarized in the "Results of Operations—Executive Overview" section. The 2013 highlighted items are summarized as follows: | [-0.025341235101222992, -0.00748836062848568, 0.0059239668771624565, -0.049127791076898575, -0.018630212172865868, 0.00441463477909565, -0.020832670852541924, -0.00919850543141365, -0.02377360127866268, -0.0113167529925704, 0.0005214645643718541, 0.019718486815690994, -0.019174348562955856, -0.005846233107149601, 0.013... |
233 | LLY | 2015 | •We recognized acquired IPR&D charges of $57.1 million (pretax), or $0.03 per share, resulting from our acquisition of rights for a CGRP monoclonal antibody (see "Results of Operations—Executive Overview—Late-Stage Pipeline" section). | [-0.00495004141703248, 0.003992707002907991, 0.011082865297794342, -0.0377967543900013, 0.014428636059165001, 0.007756698876619339, 0.005240836180746555, 0.009357702918350697, -0.02085878886282444, 0.010311770252883434, 0.018610849976539612, 0.021198594942688942, 0.010520881041884422, -0.02046670764684677, -0.001661449... |
234 | LLY | 2015 | •We recognized income of $495.4 million (pretax), or $0.29 per share, related to the transfer to Amylin Pharmaceuticals, Inc. (Amylin) of exenatide commercial rights in all markets outside the U.S. | [-0.008106444962322712, -0.023571651428937912, 0.018875686451792717, -0.01663264073431492, 0.0045779114589095116, -0.004840255714952946, -0.010506896302103996, -0.011995702050626278, -0.008545871824026108, -0.000910007453057915, 0.031323932111263275, 0.02696901373565197, 0.00423030462116003, -0.009457518346607685, -0.0... |
235 | LLY | 2015 | •We recognized charges of $120.6 million (pretax), or $0.08 per share, primarily related to severance costs, as well as asset impairment costs associated with the closure of a packaging and distribution facility in Germany. | [0.006139413453638554, -0.010274255648255348, 0.005567151587456465, -0.029135752469301224, -0.0009609372937120497, 0.007449331693351269, -0.0047037964686751366, 0.014012153260409832, -0.005924401804804802, -0.002576833590865135, -0.005342216230928898, 0.06155291572213173, 0.01259638275951147, 0.00059996556956321, 0.002... |
236 | LLY | 2015 | Numbers may not add due to rounding. | [-0.008122851140797138, -0.008246813900768757, 0.028420191258192062, -0.0178376492112875, -0.017668016254901886, -0.003810236928984523, -0.03303945064544678, -0.02540592849254608, -0.01646753028035164, -0.02672385238111019, 0.008971019648015499, 0.025014465674757957, -0.021517399698495865, 0.003350268118083477, -0.0113... |
237 | LLY | 2015 | (1) U.S. revenue includes revenue in Puerto Rico. | [-0.0022463470231741667, -0.026069914922118187, 0.008713691495358944, -0.010964890010654926, 0.01632765866816044, -0.022434359416365623, 0.003200518898665905, -0.005417755339294672, 0.014839798212051392, -0.03356097266077995, 0.012135772034525871, 0.018604733049869537, 0.0034123773220926523, -0.010945483110845089, -0.0... |
238 | LLY | 2015 | Numbers may not add due to rounding. | [-0.00807367917150259, -0.008230196312069893, 0.028460044413805008, -0.017790788784623146, -0.017621228471398354, -0.0037694559432566166, -0.03305121511220932, -0.025486217811703682, -0.01644734852015972, -0.02667314000427723, 0.00895408820360899, 0.02506883814930916, -0.021586330607533455, 0.003342294367030263, -0.011... |
239 | LLY | 2015 | In the U.S., the volume decrease in 2014 was due to lower demand for Cymbalta and Evista following patent expirations, and to a lesser extent, to wholesaler buying patterns. | [-0.008899729698896408, -0.026093721389770508, 0.03054684028029442, -0.02395830675959587, -0.030052049085497856, 0.01992185227572918, -0.01022134255617857, -0.015325503423810005, 0.0019726541358977556, -0.017382793128490448, 0.01499998290091753, 0.03296871483325958, -0.0029801398050040007, 0.0020377582404762506, 0.0054... |
240 | LLY | 2015 | (1) U.S. revenue includes revenue in Puerto Rico. | [-0.002270389348268509, -0.026054497808218002, 0.00866758357733488, -0.010976782999932766, 0.016377851366996765, -0.022458096966147423, 0.003209916641935706, -0.0053557902574539185, 0.014864258468151093, -0.0334542840719223, 0.012102275155484676, 0.01859002560377121, 0.003389413235709071, -0.010905630886554718, -0.0095... |
241 | LLY | 2015 | (2) Collaboration and other revenue consists primarily of royalties for Erbitux and revenue associated with Trajenta. | [-0.004979126155376434, -0.016768326982855797, 0.000756995112169534, -0.03846308961510658, 0.01113058626651764, 0.017282046377658844, -0.017203012481331825, -0.0033918649423867464, 0.007350138388574123, -0.023841846734285355, 0.00987263210117817, 0.019692575559020042, -0.004834230989217758, -0.015622337348759174, -0.00... |
242 | LLY | 2015 | Revenues of Alimta increased 2 percent in the U.S., driven by increased volume. Revenues outside the U.S. increased 5 percent, driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates and lower realized prices. | [-0.0030802879482507706, -0.016130436211824417, 0.0159390140324831, -0.03277133032679558, 0.0014603851595893502, 0.011791553348302841, -0.013425014913082123, -0.00791846215724945, -0.036650799214839935, -0.012384958565235138, 0.018618913367390633, 0.019116608425974846, 0.016768507659435272, -0.016104912385344505, 0.001... |
243 | LLY | 2015 | Revenues of Humalog increased 7 percent in the U.S., driven by increased demand, partially offset by lower realized prices as a result of payer contracts and greater Medicaid and Medicare utilization, as well as wholesaler buying patterns. Revenues outside the U.S. increased 6 percent, driven by increased volume and, t... | [-0.015120437368750572, -0.014507963322103024, 0.013793411664664745, -0.006915845442563295, 0.019879866391420364, -0.007611257955431938, -0.003553621703758836, -0.010380147956311703, -0.036799442023038864, -0.033022522926330566, 0.010265309363603592, 0.02458825521171093, -0.00988889392465353, -0.021334489807486534, 0.0... |
244 | LLY | 2015 | Revenues of Cialis increased 10 percent in the U.S., driven by higher realized prices, partially offset by wholesaler buying patterns. Revenues outside the U.S. increased 3 percent, driven by higher realized prices and increased volume, partially offset by the unfavorable impact of foreign exchange rates. | [-0.008903310634195805, -0.018076613545417786, 0.02558496594429016, -0.0033588302321732044, 0.013409607112407684, 0.0046059368178248405, -0.013821023516356945, -0.003002054989337921, -0.038030315190553665, -0.030290542170405388, 0.007482638116925955, 0.032476190477609634, 0.0066855186596512794, -0.0022097567562013865, ... |
245 | LLY | 2015 | Revenues of Cymbalta decreased 89 percent in the U.S. due to the loss of U.S. patent exclusivity in December 2013. Revenues outside the U.S. increased 6 percent, driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates. | [-0.006941113155335188, -0.01761677674949169, 0.034615423530340195, -0.02163463830947876, -0.008106550201773643, 0.01010260358452797, 0.004281855653971434, -0.010868830606341362, -0.018106132745742798, -0.013019416481256485, 0.02003779634833336, 0.03304433450102806, 0.0003937777946703136, 0.0037442089524120092, -0.0054... |
246 | LLY | 2015 | Revenues of Humulin increased 5 percent in the U.S., primarily driven by increased demand, partially offset by wholesaler buying patterns. Revenues outside the U.S. increased 8 percent, driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates. | [-0.019427631050348282, -0.028001267462968826, 0.004060693550854921, 0.0021895896643400192, 0.01105145551264286, -0.013898718170821667, 0.004949268884956837, -0.007643658202141523, -0.030090535059571266, -0.03949223458766937, 0.014612127095460892, 0.014790479093790054, -0.004181717988103628, -0.014790479093790054, 0.00... |
247 | LLY | 2015 | Revenues of Forteo increased 5 percent in the U.S., driven by higher realized prices, partially offset by decreased volume. Revenues outside the U.S. increased 7 percent, driven by increased volume, primarily in Japan, partially offset by the unfavorable impact of foreign exchange rates, primarily the Japanese yen. | [-0.0030060606077313423, -0.01900647208094597, -0.006075944285839796, -0.02711198665201664, 0.00026626134058460593, -0.0006003345479257405, -0.024980299174785614, -0.008271452970802784, -0.02907773293554783, -0.02079351432621479, 0.013134761713445187, 0.019095825031399727, 0.011864685453474522, -0.017525779083371162, 0... |
248 | LLY | 2015 | Revenues of Zyprexa decreased 3 percent in the U.S. Revenues outside the U.S. decreased 14 percent, driven by decreased volume, the unfavorable impact of foreign exchange rates, primarily the Japanese yen, and lower realized prices. | [-0.008945764973759651, -0.014667486771941185, 0.0348910354077816, -0.009780448861420155, 0.012233525514602661, 0.015368366613984108, -0.0017537905368953943, -0.012979005463421345, -0.010181860998272896, -0.03420289605855942, 0.011806625872850418, 0.021854683756828308, 0.014183243736624718, -0.018337544053792953, -0.00... |
249 | LLY | 2015 | Revenues of Strattera increased 1 percent in the U.S., driven by higher realized prices, partially offset by decreased volume. Revenues outside the U.S. increased 9 percent, driven by increased volume, primarily in Japan, partially offset by the unfavorable impact of foreign exchange rates, primarily the Japanese yen. | [-0.001555879833176732, -0.00998221430927515, 0.020546671003103256, -0.012078285217285156, 0.007892612367868423, 0.0022222234401851892, -0.008416630327701569, -0.007685593329370022, -0.0194727573543787, -0.014116131700575352, 0.006307621020823717, 0.016923831775784492, 0.00421801907941699, -0.00330745754763484, 0.00728... |
250 | LLY | 2015 | Revenues of Effient increased 5 percent in the U.S., driven by higher realized prices, partially offset by wholesaler buying patterns. Revenues outside the U.S. decreased 3 percent, driven by lower volume. | [-0.024860695004463196, -0.014750072732567787, -0.010701924562454224, -0.007634949404746294, 0.019480492919683456, 0.01373641099780798, 0.0034860854502767324, -0.01662144809961319, -0.023561129346489906, -0.02448382042348385, 0.013970333151519299, 0.03337285295128822, -0.0008191326051019132, -0.009369869716465473, 0.00... |
251 | LLY | 2015 | Revenues of Evista decreased 73 percent in the U.S., due to the loss of U.S. patent exclusivity in March 2014. Revenues outside the U.S. decreased 24 percent, driven primarily by the expiration of a supply agreement in 2013, and to a lesser extent the unfavorable impact of foreign exchange rates. | [-0.018078027293086052, -0.030360829085111618, 0.019334515556693077, -0.010366017930209637, -0.0010890088742598891, 0.011975090950727463, -0.018078027293086052, -0.014090604148805141, -0.013859821483492851, -0.020539715886116028, 0.00991086196154356, 0.007372245192527771, 0.017257465049624443, 0.003702149260789156, -0.... |
252 | LLY | 2015 | Animal health product revenues in the U.S. increased 4 percent, driven by increased volume in food animal products and higher realized prices, partially offset by decreased volume in companion animal products due to competitive pressure. Revenues outside the U.S. increased 16 percent, driven by increased volume in food... | [-0.0010912007419392467, -0.00831758975982666, 0.0012102993205189705, -0.019287535920739174, 0.003682400332763791, -0.002592808799818158, -0.007609435357153416, -0.017394835129380226, -0.023961352184414864, -0.01805148646235466, 0.0039012841880321503, 0.01908152922987938, -0.0037210267037153244, -0.011626599356532097, ... |
253 | LLY | 2015 | Gross margin as a percent of total revenue was 74.9 percent in 2014, a decrease of 3.9 percentage points compared with 2013, driven primarily by lower sales of Cymbalta and Evista following U.S. patent expirations. | [-0.0038846752140671015, -0.011769033037126064, 0.022605232894420624, -0.020841794088482857, -0.015334244817495346, -0.0037505007348954678, -0.016663212329149246, -0.013583584688603878, -0.01575593650341034, -0.01845220848917961, 0.0182860866189003, 0.045926064252853394, -0.007213484030216932, 0.0024311167653650045, 0.... |
254 | LLY | 2015 | Research and development expenses decreased 14 percent to $4.73 billion in 2014, driven primarily by lower late-stage clinical development costs. Research and development expenses in 2013 included $97.2 million of milestone payments made to Boehringer Ingelheim following regulatory submissions for empagliflozin. | [-0.007983241230249405, -0.02115883305668831, 0.008009202778339386, -0.029440633952617645, -0.005964714102447033, 0.011572454124689102, 0.00991739146411419, -0.012409720569849014, -0.01529147569090128, 0.002456631511449814, 0.006253538653254509, 0.026493975892663002, -6.5208638261538e-05, -0.00861281342804432, 0.001571... |
255 | LLY | 2015 | Marketing, selling, and administrative expenses decreased 7 percent to $6.62 billion in 2014, driven primarily by the reduction in U.S. sales and marketing activities for Cymbalta and Evista, as well as ongoing cost containment efforts, partially offset by an additional $119.0 million charge in 2014 associated with the... | [-0.011833255179226398, -0.011516822502017021, 0.00774600263684988, -0.040397875010967255, -0.03362094983458519, -0.0020370339043438435, -0.009440234862267971, -0.007271354086697102, -0.00422569178044796, -0.009783037006855011, 0.02112186700105667, 0.013712072744965553, 0.008279982954263687, 0.02130645141005516, -0.005... |
256 | LLY | 2015 | We recognized acquired IPR&D charges of $200.2 million in 2014 resulting from our collaboration agreements with Adocia, AstraZeneca UK Limited, and Immunocore Limited in addition to charges associated with the transfer of commercial rights to us, from Boehringer Ingelheim, of the new insulin glargine product in certain... | [-0.012414611876010895, -0.008433948270976543, 0.004233615472912788, -0.031126394867897034, 0.008094459772109985, 0.019051270559430122, -0.0003760994877666235, 0.01461795624345541, -0.019796812906861305, -0.015509944409132004, 0.015097233466804028, 0.0011025040876120329, -0.0036611456889659166, -0.007368887774646282, -... |
257 | LLY | 2015 | We recognized asset impairment, restructuring, and other special charges of $468.7 million in 2014. These charges included $225.5 million of severance costs and $243.2 million of asset impairment and other special charges consisting primarily of a $180.8 million asset impairment charge related to our decision to close ... | [-0.02396390773355961, -0.00840309914201498, 0.013856591656804085, -0.03767629712820053, 0.003673897823318839, 0.007544436026364565, -0.004208104219287634, 0.006947960238903761, -0.0005604251055046916, -0.013502639718353748, -0.002875865437090397, 0.04236944764852524, -0.0042998697608709335, 0.008344106376171112, -0.00... |
258 | LLY | 2015 | Other—net, (income) expense was income of $340.5 million in 2014, compared with income of $518.9 million in 2013. Other income in 2014 included net gains of $216.4 million on investments and $92.0 million of income related to the transfer of commercial rights to linagliptin and empagliflozin in certain countries from u... | [-0.016501782462000847, -0.029805442318320274, 0.01641003228724003, -0.017183348536491394, 0.00448916619643569, 0.0005353412707336247, -0.0001783788320608437, 0.0035683957394212484, -0.0033783435355871916, -0.01755034737288952, 0.023461628705263138, 0.025362150743603706, -0.012648307718336582, -0.002133173169568181, 0.... |
259 | LLY | 2015 | Our effective tax rate was 20.3 percent in 2014, compared with 20.5 percent in 2013. See Note 13 to the consolidated financial statements for additional information. | [-0.03413177281618118, -0.010621121153235435, -0.0061744200065732, -0.04144039750099182, -0.006090519949793816, -0.016991307958960533, -0.007302409503608942, -0.01649412326514721, -0.008756676688790321, -0.022336050868034363, 0.016767574474215508, 0.019328080117702484, 0.0010813780827447772, 0.004132852889597416, 0.010... |
260 | LLY | 2015 | As of December 31, 2015, cash and cash equivalents was $3.67 billion, a decrease of $205.2 million, compared with $3.87 billion at December 31, 2014. Refer to the Consolidated Statements of Cash Flows for additional details on the significant sources and uses of cash for the years ended December 31, 2015 and December 3... | [-0.028559938073158264, -0.01593780145049095, -0.008735020644962788, -0.010242140851914883, 0.003780361032113433, 0.004361230414360762, -0.013375695794820786, -0.019718162715435028, -0.019730722531676292, -0.011573431082069874, 0.03707516938447952, 0.007705154828727245, -0.016000598669052124, 0.011196650564670563, 0.00... |
261 | LLY | 2015 | In addition to our cash and cash equivalents, we held total investments of $4.43 billion and $5.52 billion as of December 31, 2015 and December 31, 2014, respectively. See Note 7 to the consolidated financial statements for additional details. | [-0.010876459069550037, -0.026858583092689514, -0.002014393685385585, -0.018192889168858528, -0.014974926598370075, 0.0069300211034715176, -0.0337759368121624, -0.007715507876127958, 0.010547061450779438, 0.006347240414470434, 0.01639387011528015, 0.015608384273946285, -0.01767345517873764, 0.010762437246739864, 0.0183... |
262 | LLY | 2015 | As of December 31, 2015, total debt was $7.98 billion, a slight decrease of $43.0 million compared with $8.02 billion at December 31, 2014. This decrease is due primarily to $2.68 billion of net repayments of short-term commercial paper borrowings, the repayment of $1.78 billion of fixed-rate notes in connection with t... | [-0.034980565309524536, 0.0015321719693019986, 0.006811801344156265, -0.015376497991383076, -0.0030450106132775545, -0.013739603571593761, -0.021112073212862015, 0.008487362414598465, -0.010691370815038681, -0.008461585268378258, 0.027788540348410606, 0.019281845539808273, -0.02191118709743023, 0.007726915646344423, -0... |
263 | LLY | 2015 | For the 130th consecutive year, we distributed dividends to our shareholders. Dividends of $2.00 per share and $1.96 per share were paid in 2015 and 2014, respectively. In the fourth quarter of 2015, effective for the dividend to be paid in the first quarter of 2016, the quarterly dividend was increased to $0.51 per sh... | [-0.02838415652513504, -0.0020567772444337606, -0.016163552179932594, -0.05282536894083023, -0.007911168038845062, -0.007525719236582518, -0.01790754683315754, -0.0020014874171465635, -0.020902669057250023, -0.007266647648066282, 0.0047928281128406525, 0.02094058319926262, -0.0020867916755378246, -0.007456212304532528,... |
264 | LLY | 2015 | Capital expenditures of $1.07 billion during 2015 were $96.4 million less than in 2014. We expect 2016 capital expenditures to be approximately $1.1 billion. | [-0.0025243402924388647, -0.0024387419689446688, -0.004137786105275154, -0.013049691915512085, -0.0018734707264229655, 0.007978401146829128, -0.002878038678318262, -0.015582107938826084, 0.0038567655719816685, 0.0038535352796316147, 0.009509478695690632, 0.024070868268609047, -0.014496786519885063, -0.00252757035195827... |
265 | LLY | 2015 | In 2015, we repurchased $749.5 million of shares under the $5.00 billion share repurchase program previously announced in October 2013. | [-0.030086280778050423, -0.0166635625064373, -0.008242467418313026, -0.04054885357618332, -0.03138772398233414, -0.009448214434087276, -0.03756319358944893, -0.010449814610183239, -0.003933034837245941, 0.017850171774625778, 0.010979323647916317, 0.014124475419521332, 0.007789514027535915, -0.022226590663194656, 0.0047... |
266 | LLY | 2015 | See "Results of Operations—Executive Overview—Other Matters" section for information regarding the actual or anticipated effect of losses of exclusivity for Cymbalta (U.S. and Europe), Evista (U.S.), Alimta (U.S., Europe, and Japan), and Zyprexa (Japan). | [-0.01991409808397293, -0.027056170627474785, 0.03423874452710152, -0.035534851253032684, -0.020440639927983284, 0.03604789078235626, -0.007520103361457586, 0.0017365767853334546, -0.004769257735460997, -0.008120900951325893, 0.007938636466860771, 0.03375270590186119, -0.016741342842578888, 0.0037634267937391996, -0.00... |
267 | LLY | 2015 | At December 31, 2015, we had an aggregate of $7.12 billion of cash and investments at our foreign subsidiaries. A significant portion of this amount would be subject to tax payments if such cash and investments were repatriated to the U.S. We record U.S. deferred tax liabilities for certain unremitted earnings, but whe... | [-0.00577228469774127, -0.026874879375100136, -0.004470532760024071, -0.030518492683768272, -0.006783322896808386, -0.006486149039119482, -0.020246604457497597, -0.0046740323305130005, 0.012474853545427322, -0.006776862777769566, 0.02395481988787651, 0.021448221057653427, -0.018218068405985832, 0.012268124148249626, -0... |
268 | LLY | 2015 | Both domestically and abroad, we continue to monitor the potential impacts of the economic environment; the creditworthiness of our wholesalers and other customers, including foreign government-backed agencies and suppliers; the uncertain impact of health care legislation; and various international government funding l... | [-0.018932679668068886, -0.029444951564073563, 0.004954934120178223, -0.015622771345078945, 0.00590487802401185, 0.017635196447372437, 0.005908187944442034, 0.017012933269143105, 0.0018419644329696894, -0.024572765454649925, 0.004584224428981543, 0.009890008717775345, -0.0019644310232251883, -0.007559832651168108, -0.0... |
269 | LLY | 2015 | In the normal course of business, our operations are exposed to fluctuations in interest rates and currency values. These fluctuations can vary the costs of financing, investing, and operating. We address a portion of these risks through a controlled program of risk management that includes the use of derivative financ... | [-0.018555525690317154, -0.034215863794088364, 0.0052804285660386086, -0.003257086966186762, -0.027399009093642235, 0.014831259846687317, -0.024767020717263222, 0.002840903587639332, 0.002075981581583619, -0.01868712529540062, -0.009297502227127552, 0.029320361092686653, 0.007935447618365288, 0.015568217262625694, -0.0... |
270 | LLY | 2015 | Our primary interest rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest rate exposures, we strive to achieve an acceptable balance between fixed and floating rate debt positions and may enter into interest rate derivatives to help maintain that balance. Bas... | [-0.03257507458329201, -0.02692004106938839, 0.010443568229675293, -0.020900167524814606, -0.008306643925607204, 0.008515124209225178, -0.03867312893271446, 0.008534668944776058, -0.015870576724410057, -0.008195888251066208, 0.012358983047306538, 0.021499548107385635, 0.0021320385858416557, 0.029708467423915863, -0.003... |
271 | LLY | 2015 | Our foreign currency risk exposure results from fluctuating currency exchange rates, primarily the U.S. dollar against the euro, Japanese yen, and British pound, and the British pound against the euro. We face foreign currency exchange exposures when we enter into transactions arising from subsidiary trade and loan pay... | [-0.0037644298281520605, -0.025507258251309395, -0.0020817946642637253, -0.0170697420835495, -0.01900388114154339, 0.00762621546164155, -0.016952915117144585, -0.008943766355514526, 0.004296642262488604, -0.004501089919358492, -0.004913229960948229, 0.027882741764187813, -0.0032419529743492603, 0.019120708107948303, 0.... |
272 | LLY | 2015 | We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources. We acquire and coll... | [-0.008406060747802258, -0.015584959648549557, 0.008596953004598618, -0.01273521687835455, -0.0087196696549654, 0.019075555726885796, -0.013491966761648655, -0.0076697636395692825, -0.006128993351012468, -0.012128452770411968, 0.028415622189641, 0.028961028903722763, -0.0019719814881682396, 0.012033007107675076, -0.010... |
273 | LLY | 2015 | Individually, these arrangements are not material in any one annual reporting period. However, if milestones for multiple products covered by these arrangements were reached in the same reporting period, the aggregate charge to expense could be material to the results of operations or cash flows in that period. See Not... | [-0.006919656880199909, -0.020156679674983025, 0.0115238381549716, -0.029231199994683266, -0.016529547050595284, 0.01027241162955761, -0.011965518817305565, -0.029739802703261375, -0.004547298885881901, -0.034611668437719345, 0.03056962601840496, 0.04697871580719948, -0.010734167881309986, 0.014240841381251812, -0.0083... |
274 | LLY | 2015 | (1) Our long-term debt obligations include both our expected principal and interest obligations and our interest rate swaps. We used the interest rate forward curve at December 31, 2015, to compute the amount of the contractual obligation for interest on the variable rate debt instruments and swaps. | [-0.015033943578600883, -0.00032378299511037767, -0.005938732996582985, -0.018144864588975906, 0.001152765122242272, 0.007653644308447838, -0.027178246527910233, 0.016374632716178894, -0.020865291357040405, -0.004962502978742123, 0.035196349024772644, 0.027542706578969955, -0.019238241016864777, 0.011552056297659874, -... |
275 | LLY | 2015 | •Purchase obligations consisting primarily of all open purchase orders as of December 31, 2015. Some of these purchase orders may be cancelable; however, for purposes of this disclosure, we have not distinguished between cancelable and noncancelable purchase obligations. | [-0.013508576899766922, -0.01721757836639881, -0.012994522228837013, 0.0016511566936969757, -0.023503361269831657, -0.014263391494750977, -0.040655869990587234, -0.0007832827395759523, -0.030322721228003502, -0.0042686061933636665, 0.02865692414343357, 0.02178550884127617, -0.020952610298991203, 0.01652783527970314, -0... |
276 | LLY | 2015 | •Contractual payment obligations with each of our significant vendors, which are noncancelable and are not contingent. | [-0.0037335280794650316, -0.010332473553717136, -0.0022273887880146503, -0.0076563432812690735, 0.006781705655157566, 0.0002447680162731558, -0.03456776961684227, -0.00228776503354311, 0.009353401139378548, -0.020194992423057556, 0.01686614751815796, 0.03616039454936981, -0.00990820862352848, 0.014620808884501457, -0.0... |
277 | LLY | 2015 | (3) We have included long-term liabilities consisting primarily of our nonqualified supplemental pension funding requirements and deferred compensation liabilities. We excluded long-term income taxes payable of $868.9 million, because we cannot reasonably estimate the timing of future cash outflows associated with tho... | [-0.006626139860600233, -0.004194258246570826, 0.009753783233463764, -0.04174566641449928, -0.02311764843761921, -0.002353116637095809, -0.027594149112701416, -0.0008270367980003357, -0.020308347418904305, 0.014059625566005707, 0.022684438154101372, 0.014059625566005707, -0.00019106765103060752, 0.022290611639618874, -... |
278 | LLY | 2015 | The contractual obligations table is current as of December 31, 2015. We expect the amount of these obligations to change materially over time as new contracts are initiated and existing contracts are completed, terminated, or modified. | [-0.01026289165019989, -0.021560028195381165, -0.019252866506576538, -0.027871573343873024, -0.02220974490046501, 0.003623171942308545, -0.05370117351412773, 0.02154676802456379, -0.01593797840178013, -0.016760069876909256, 0.04102504625916481, 0.00987173430621624, -0.017887132242321968, 0.0203799270093441, 0.001207447... |
279 | LLY | 2015 | In preparing our financial statements in accordance with accounting principles generally accepted in the U.S., we must often make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. Some of those judgments can be subjective and complex, and con... | [-0.004968141205608845, -0.005221193190664053, 8.223178883781657e-05, -0.03956575319170952, 0.0018466366454958916, 0.002240628469735384, -0.021730413660407066, 0.013645571656525135, -9.169119584839791e-05, -0.02137165702879429, 0.009795342572033405, 0.022025106474757195, -0.01795065402984619, 0.005929097067564726, -0.0... |
280 | LLY | 2015 | We recognize revenue from sales of products at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership. Provisions for returns, rebates, and discounts are established in the same period the related sales are recorded. | [0.0016941195353865623, -0.03514115884900093, -0.004356773104518652, -0.02525363117456436, -0.003029522718861699, -0.014387786388397217, -0.001992506207898259, -0.002241977257654071, 0.004382861778140068, -0.029897376894950867, 0.010487562045454979, 0.03242795914411545, -0.014270388521254063, 0.010435384698212147, 0.00... |
281 | LLY | 2015 | We regularly review the supply levels of our significant products sold to major wholesalers in the U.S. and in major markets outside the U.S., primarily by reviewing periodic inventory reports supplied by our major wholesalers and available prescription volume information for our products, or alternative approaches. We... | [-0.01154625415802002, -0.010187473148107529, 0.005499342922121286, -0.0038938187062740326, -0.015196708962321281, 0.009268099442124367, -0.003449341980740428, 0.0004875723388977349, 0.017887229099869728, -0.02172696776688099, 0.005306679755449295, 0.018698440864682198, -0.010410556569695473, 0.025188138708472252, 0.01... |
282 | LLY | 2015 | When sales occur, we estimate a reserve for future product returns related to those sales. This estimate is based on several factors, including: historical return rates, expiration date by product (generally, 24 to 36 months after the initial sale of a product to our customer), and estimated levels of inventory in the ... | [-0.00447830930352211, -0.019737733528017998, 0.0018193131545558572, -0.01138927973806858, -0.028086185455322266, -0.005058830603957176, -0.005632441490888596, -0.0016638162778690457, -0.007215053774416447, 0.006396103650331497, 0.016683083027601242, 0.05172170698642731, -0.020622337237000465, 0.02460305579006672, -0.0... |
283 | LLY | 2015 | We establish sales rebate and discount accruals in the same period as the related sales. The rebate and discount amounts are recorded as a deduction to arrive at our net product sales. Sales rebates and discounts that require the use of judgment in the establishment of the accrual include Medicaid, managed care, Medica... | [-0.007532619871199131, -0.006332733668386936, 0.016278458759188652, -0.02898392267525196, -0.010918966494500637, 0.0017215036787092686, -0.005352826323360205, -0.008325878530740738, -0.010792311280965805, -0.010805643163621426, 0.016678420826792717, 0.02570423297584057, -0.020291412249207497, 0.006739361677318811, -0.... |
284 | LLY | 2015 | The largest of our sales rebate and discount amounts are rebates associated with sales covered by Medicaid and managed care contracts. In determining the appropriate accrual amount, we consider our historical Medicaid and managed care rebate payments by product as a percentage of our historical sales as well as any sig... | [-0.006795648485422134, 0.002404328202828765, 0.008522439748048782, -0.03668501228094101, -0.009806550107896328, 0.0004908344126306474, -0.011016317643225193, 0.008184515871107578, -0.008826570585370064, -0.0202078465372324, 0.02761513739824295, 0.041740354150533676, -0.01649068482220173, 0.010739220306277275, -0.01655... |
285 | LLY | 2015 | Most of our rebates outside the U.S. are contractual or legislatively mandated and are estimated and recognized in the same period as the related sales. In some large European countries, government rebates are based on the anticipated budget for pharmaceutical payments in the country. A best estimate of these rebates, ... | [0.007552118506282568, -0.022811029106378555, -0.003658372675999999, -0.02193678542971611, -0.014324142597615719, -0.013328850269317627, -0.00180901144631207, 0.007397444453090429, -0.02087424322962761, 0.00215534633025527, 0.013342299498617649, 0.018036315217614174, -0.023712171241641045, 0.0025655683130025864, -0.020... |
286 | LLY | 2015 | We believe that our accruals for sales returns, rebates, and discounts are reasonable and appropriate based on current facts and circumstances. Our global rebate and discount liabilities are included in sales rebates and discounts on our consolidated balance sheet. Our global sales return liability is included in other... | [-0.02768542803823948, -0.00884873978793621, -0.0034673018380999565, -0.030652670189738274, -0.024638706818223, -0.007305508945137262, -0.024930132552981377, 0.0047654700465500355, -0.0012021304573863745, -0.014597770757973194, 0.02821529284119606, 0.02802984043955803, -0.022572234272956848, 0.009921715594828129, 0.008... |
287 | LLY | 2015 | The portion of our global sales return, rebate, and discount liability resulting from sales of our products in the U.S. was 87 percent and 88 percent as of December 31, 2015 and 2014, respectively. | [0.001511195208877325, -0.017893323674798012, -0.011819619685411453, -0.030310671776533127, -0.02153111808001995, -0.008882389403879642, -0.014872538857161999, 0.009126623161137104, 0.004900739528238773, -0.015065355226397514, 0.021029796451330185, 0.03208458051085472, -0.02582448720932007, -0.010566315613687038, 0.012... |
288 | LLY | 2015 | The following represents a roll-forward of our most significant U.S. pharmaceutical sales return, rebate, and discount liability balances, including Medicaid and managed care: | [-0.02069537155330181, -0.014863039366900921, 0.0010498869232833385, -0.01866615004837513, -0.01988905854523182, 0.0014404448447749019, -0.016193456947803497, 0.022375190630555153, -0.01235674973577261, -0.0033697171602398157, 0.029484184458851814, 0.03725166991353035, -0.0056710694916546345, 0.017335733398795128, 0.00... |
289 | LLY | 2015 | (1) Adjustments of the estimates for these returns, rebates, and discounts to actual results were less than 1.5 percent of consolidated net sales for each of the years presented. | [-0.033671483397483826, -0.016756638884544373, 0.013243150897324085, 0.0006596031598746777, -0.01692802831530571, -0.0003691470483317971, -0.0028444097843021154, -0.011779746040701866, 0.0018374953651800752, -0.026697242632508278, 0.011450150981545448, 0.05827249959111214, -0.010896430350840092, 0.02025035209953785, 0.... |
290 | LLY | 2015 | Product litigation liabilities and other contingencies are, by their nature, uncertain and are based upon complex judgments and probabilities. The factors we consider in developing our product litigation liability reserves and other contingent liability amounts include the merits and jurisdiction of the litigation, the... | [0.023214153945446014, -0.007699338253587484, 0.0006199777708388865, -0.015453330241143703, 0.002022186294198036, 0.005834280978888273, -0.007111811079084873, 0.02098701521754265, -0.027299515902996063, -0.01962067373096943, 0.007590030785650015, 0.016013531014323235, -0.019142454490065575, 0.0152893690392375, -0.01904... |
291 | LLY | 2015 | We also consider the insurance coverage we have to diminish the exposure for periods covered by insurance. In assessing our insurance coverage, we consider the policy coverage limits and exclusions, the potential for denial of coverage by the insurance company, the financial condition of the insurers, and the possibili... | [-0.002140843542292714, -0.005563165992498398, 0.015323932282626629, -0.03898924961686134, -0.028656695038080215, 0.017355462536215782, 0.0012966145295649767, 0.021875957027077675, 0.010574724525213242, -0.008812270127236843, -0.00814630463719368, 0.03436112776398659, 0.007735962513834238, -0.0069892737083137035, 0.003... |
292 | LLY | 2015 | The litigation accruals and environmental liabilities and the related estimated insurance recoverables have been reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. | [-0.00859388429671526, -0.01836732216179371, 0.010628936812281609, -0.0239669568836689, -0.014802739024162292, -0.000285166606772691, -0.009501232765614986, 0.0005504849832504988, -0.00650374311953783, -0.02417435124516487, 0.0265334565192461, 0.01220383495092392, 0.011737198568880558, 0.011277043260633945, 0.000613270... |
293 | LLY | 2015 | Defined benefit pension plan and retiree health benefit plan costs include assumptions for the discount rate, retirement age, and expected return on plan assets. These assumptions have a significant effect on the amounts reported. In addition to the analysis below, see Note 14 to the consolidated financial statements f... | [-0.012219717726111412, -0.006901758257299662, 0.008054197765886784, -0.04133329167962074, -0.011897807940840721, 0.024799974635243416, -0.011814110912382603, -0.01547745056450367, -0.0335044302046299, -0.0009142254712060094, -0.005601240787655115, 0.03602821007370949, -0.025765705853700638, 0.010288255289196968, -0.00... |
294 | LLY | 2015 | Annually, we evaluate the discount rate and the expected return on plan assets in our defined benefit pension and retiree health benefit plans. We use an actuarially determined, plan-specific yield curve of high quality, fixed income debt instruments to determine the discount rates. In evaluating the expected return on... | [-0.027623191475868225, -0.020240217447280884, 0.007906542159616947, -0.043608590960502625, -0.0035821341443806887, 0.01974978670477867, -0.02126084454357624, 2.51603455581062e-06, -0.026006095111370087, -0.006050857715308666, -0.000350633286871016, 0.03602679446339607, 0.0029757230076938868, 0.0262314286082983, -0.013... |
295 | LLY | 2015 | If the 2015 discount rate for the U.S. defined benefit pension and retiree health benefit plans (U.S. plans) were to change by a quarter percentage point, income before income taxes would change by $42.9 million. As of January 1, 2016, we changed the method used to estimate the service and interest cost components of t... | [-0.03392209857702255, -0.0036955182440578938, 0.018602008000016212, -0.037204016000032425, 0.004650502000004053, 0.00016718520782887936, -0.008588128723204136, -0.012320635840296745, -0.028407404199242592, -0.007162378169596195, 0.004166285041719675, 0.0456240139901638, -0.004028417635709047, 0.017324212938547134, -0.... |
296 | LLY | 2015 | If the 2015 expected return on plan assets for U.S. plans were to change by a quarter percentage point, income before income taxes would change by $22.7 million. If our assumption regarding the 2015 expected age of future retirees for U.S. plans were adjusted by one year, our income before income taxes would be affecte... | [-0.016230182722210884, -0.027342023327946663, 0.004259760025888681, -0.03458195924758911, 0.012842264957726002, 0.002506131073459983, -0.027076825499534607, 0.0004216250672470778, -0.026851406320929527, 0.016906440258026123, 0.01863023452460766, 0.03980638086795807, -0.0070741851814091206, 0.028323261067271233, 0.0079... |
297 | LLY | 2015 | We review the carrying value of long-lived assets (both intangible and tangible) for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. We determine impairment by comparing the projected undiscounted cash flows to be g... | [-0.012911719270050526, -0.00774571904912591, 0.02116287872195244, -0.021648628637194633, -0.0056648775935173035, 0.003561061341315508, -0.011034367606043816, 0.01734253391623497, 0.0077260262332856655, -0.0010305744362995028, -0.004926408641040325, 0.03408116474747658, -0.01223560981452465, 0.020178254693746567, -0.00... |
298 | LLY | 2015 | Goodwill and indefinite-lived intangible assets are reviewed for impairment at least annually and when certain impairment indicators are present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. | [-0.009156637825071812, -0.015621662139892578, 0.017257235944271088, -0.01961400732398033, -0.015840597450733185, 0.006197794806212187, -0.030728183686733246, -0.00021289827418513596, 0.005186829715967178, -0.015570147894322872, -0.0013506363611668348, 0.03018728457391262, -0.003548036329448223, 0.0203094482421875, -0.... |
299 | LLY | 2015 | Several methods may be used to determine the estimated fair value of acquired IPR&D, all of which require multiple assumptions. We utilize the “income method,” as described in Note 8 to the consolidated financial statements. | [-0.019772466272115707, -0.021675419062376022, 0.017178714275360107, -0.03339292109012604, -0.0030776357743889093, 0.012532120570540428, -0.03375786915421486, -0.0006745057180523872, 0.0034214055631309748, -0.007520575542002916, 0.0071295578964054585, 0.021714521571993828, 0.011567609384655952, 0.012036831118166447, -0... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.